The Stanford Biodesign program created another promising start-up in Zenflow. Co-founder and CEO Nick Damiano explains how the program's fellows identified the opportunity in BPH and found the right tech to excite investors. Zenflow drew some early capital from unusual sources before embarking on an exhausting pursuit of the right Series A syndicate. Damiano shares some advice for other capital-hungry start-ups.
Overview: Great to see a monster Medtech Series A!
Surprises: Zenflow is working out of some offices with great karma.
Regrets: None. I'm feeling good about this one. I could have asked about the broader team.
Medtech Talk